COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Hemab Therapeutics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$32.09+2.02 (+6.72%)
Close on Oct 19, 2026
- Market cap
- $966.27M
- P/E (TTM)
- –
- Dividend yield
- –
Hemab Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Hemab Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.50B | $166.30M |
| Enterprise Value | $1.04B | $88.19M |
| PB Ratio | 3.30 | 2.03 |
| P/TBV Ratio | 3.30 | 2.29 |
Balance sheet
| Measure | Hemab Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $457.46M | $61.43M |
| Net Cash (Debt) | $457.46M | $15.35M |
| Net Cash Per Share | $9.79 | $0.66 |
| Equity (Book Value) | $454.27M | $49.09M |
| Book Value Per Share | $9.72 | $1.37 |
| Tangible Book Value | $454.27M | $23.52M |
| Working Capital | $451.05M | $76.81M |
Financial position
| Measure | Hemab Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 35.85 | 3.34 |
| Quick Ratio | 35.34 | 2.44 |
Shares
| Measure | Hemab Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 46,712,100 | 58,127,000 |
| Float | 37,600,700 | 49,136,700 |
| Shares Held by Insiders | 19.5% | 11.6% |
| Shares Held by Institutions | 77.5% | 59.4% |
Scores
| Measure | Hemab Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 67.05 | -0.22 |
Calculated by StockData from Hemab Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.